[{"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-001", "question": "A 27-year-old G1P0 at 9 weeks' gestation presents with intractable nausea and vomiting, 7-kg weight loss, new-onset jaundice, and confusion over 3 days. She has no prior liver disease or alcohol use. Vitals: T 37.2°C, HR 122, BP 100/62, RR 18, SpO2 98% RA. Exam: scleral icterus, moderate right upper quadrant tenderness without rebound, asterixis. Labs: Na 132, K 3.1, bicarbonate 19, creatinine 1.2 mg/dL (baseline 0.6), AST 545 U/L, ALT 510 U/L, ALP 225 U/L, total bilirubin 12.4 mg/dL (direct 8.1), INR 2.6, ammonia 102 µmol/L, β-hCG markedly elevated for gestational age, thyroid studies: TSH low, free T4 and T3 mildly elevated. Abdominal ultrasound: single live intrauterine pregnancy, normal hepatic and portal vasculature, no biliary dilation, mild fatty liver change. Viral hepatitis serologies and autoimmune markers are pending. She is receiving IV fluids and antiemetics but continues to deteriorate neurologically. Which of the following is the most appropriate immediate next management step?", "options": ["Administer high-dose IV methylprednisolone and defer pregnancy decisions until serologies return", "Urgently proceed with uterine evacuation and initiate N-acetylcysteine infusion", "Start high-dose IV thiamine and parenteral nutrition while continuing pregnancy", "List for emergent liver transplantation without altering pregnancy status", "Administer propylthiouracil and beta-blockers to treat probable gestational thyrotoxicosis and reassess"], "answer": "B", "answer_index": 1, "explanation": "This presentation is most consistent with hyperemesis gravidarum-associated acute liver failure with encephalopathy and coagulopathy; maternal survival takes precedence, and rapid uterine evacuation plus N-acetylcysteine offers the best chance to reverse fulminant hepatic injury. Steroids (A) address autoimmune hepatitis, which is unconfirmed and too slow. Thiamine and nutrition (C) are supportive but insufficient in fulminant failure with encephalopathy. Immediate transplantation listing (D) may be needed but should follow rapid removal of the precipitating factor. Treating mild gestational thyrotoxicosis alone (E) will not address the primary life-threatening hepatic process.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: U (underspecified, with elements of M)\\nVerdict on keyed answer: Not uniquely determinable\\n\\nKey clues: 9-week pregnancy, intractable hyperemesis, marked weight loss, acute severe hepatocellular injury (AST/ALT >500), hyperbilirubinemia, INR 2.6, encephalopathy (confusion, asterixis), elevated ammonia, normal hepatic/portal flow, no biliary dilation. This is acute liver failure in early pregnancy with multiorgan involvement. β-hCG is high and thyroid tests show mild thyrotoxicosis typical of hyperemesis. Etiology (viral, autoimmune, drug, etc.) is not yet defined.\\n\\nThe question asks for the most appropriate *immediate next step*. The keyed answer (B: urgent uterine evacuation + N-acetylcysteine) assumes that terminating pregnancy clearly improves maternal survival in this setting and that hyperemesis-related liver failure is the precipitant, but that causal link is not firmly established from given data; other causes (e.g., acute viral, autoimmune) remain possible. Emergent listing for transplant (D) is also reasonable and guideline-consistent as an immediate step once acute liver failure with encephalopathy is recognized, especially before knowing etiology, making B vs D a near-tie.\\n\\nMain medical issue: the strong claim that uterine evacuation is standard first step for such early-pregnancy acute liver failure is not clearly evidence-based. Minimal fix: explicitly state confirmed diagnosis/etiology (e.g., negative viral/autoimmune workup, clear hyperemesis-induced hepatic failure with prior improvement after evacuation) or modify options so transplant listing is clearly secondary, making B uniquely best.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"U\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (underspecified, with elements of M)\nVerdict on keyed answer: Not uniquely determinable\n\nKey clues: 9-week pregnancy, intractable hyperemesis, marked weight loss, acute severe hepatocellular injury (AST/ALT >500), hyperbilirubinemia, INR 2.6, encephalopathy (confusion, asterixis), elevated ammonia, normal hepatic/portal flow, no biliary dilation. This is acute liver failure in early pregnancy with multiorgan involvement. β-hCG is high and thyroid tests show mild thyrotoxicosis typical of hyperemesis. Etiology (viral, autoimmune, drug, etc.) is not yet defined.\n\nThe question asks for the most appropriate *immediate next step*. The keyed answer (B: urgent uterine evacuation + N-acetylcysteine) assumes that terminating pregnancy clearly improves maternal survival in this setting and that hyperemesis-related liver failure is the precipitant, but that causal link is not firmly established from given data; other causes (e.g., acute viral, autoimmune) remain possible. Emergent listing for transplant (D) is also reasonable and guideline-consistent as an immediate step once acute liver failure with encephalopathy is recognized, especially before knowing etiology, making B vs D a near-tie.\n\nMain medical issue: the strong claim that uterine evacuation is standard first step for such early-pregnancy acute liver failure is not clearly evidence-based. Minimal fix: explicitly state confirmed diagnosis/etiology (e.g., negative viral/autoimmune workup, clear hyperemesis-induced hepatic failure with prior improvement after evacuation) or modify options so transplant listing is clearly secondary, making B uniquely best.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-002", "question": "A 63-year-old man with long-standing hypertension and ischemic cardiomyopathy (EF 30%) presents with acute right hemiplegia and aphasia 45 minutes after symptom onset. NIHSS is 18. Noncontrast CT head shows no hemorrhage. CT angiography shows left M1 occlusion with favorable collaterals; CT perfusion suggests a large salvageable penumbra. ECG shows sinus rhythm with frequent PVCs. High-sensitivity troponin is mildly elevated and flat on serial testing. You plan IV thrombolysis and urgent mechanical thrombectomy. Which of the following additional acute management steps is most appropriate?", "options": ["Initiate IV unfractionated heparin infusion before mechanical thrombectomy due to high cardioembolic risk", "Administer IV labetalol to reduce blood pressure to <140/90 mm Hg prior to thrombolysis", "Start high-dose statin and delay any antiplatelet therapy until 24 hours after thrombolysis", "Begin dual antiplatelet therapy with aspirin and clopidogrel immediately after thrombolysis", "Place an intra-aortic balloon pump preemptively to support cerebral perfusion during thrombectomy"], "answer": "C", "answer_index": 2, "explanation": "The correct step is to start high-intensity statin immediately and delay antiplatelets until 24 hours after thrombolysis and repeat imaging, per acute ischemic stroke guidelines. Heparin before thrombectomy (A) increases hemorrhagic risk with no proven benefit. Lowering BP below 140/90 (B) before tPA is too aggressive and can worsen cerebral perfusion; only treat if >185/110 to that threshold. Dual antiplatelets immediately after tPA (D) markedly increases hemorrhage risk. Intra-aortic balloon pump (E) has no role in this setting and carries procedural risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Acute ischemic stroke within 45 minutes, large-vessel M1 occlusion, large penumbra, no hemorrhage, patient is candidate for IV thrombolysis and urgent mechanical thrombectomy. The question asks for an additional acute management step consistent with current stroke guidelines.\\nChoice C correctly reflects guideline-based care: initiate high-intensity statin early after ischemic stroke and delay antiplatelet therapy for 24 hours post–IV thrombolysis until repeat imaging excludes hemorrhagic transformation. \\nOption A (IV heparin before thrombectomy) is contraindicated: routine anticoagulation in acute ischemic stroke, especially around alteplase and thrombectomy, increases hemorrhage risk without outcome benefit. \\nOption B describes excessive blood pressure lowering; guidelines permit BP up to 185/110 before tPA and 180/105 after; further lowering may impair perfusion of penumbra. \\nOption D (immediate dual antiplatelet therapy after tPA) significantly increases intracranial hemorrhage risk and is avoided. \\nOption E (IABP) has no evidence-based role for cerebral perfusion in this setting and carries procedural risk. \\nMain medical accuracy issues: none substantive; management logic is guideline-consistent. \\nMinimal fix: Clarify in stem that baseline LDL is elevated or that high-intensity statin is indicated per secondary stroke prevention guidelines to reinforce rationale, though not strictly necessary for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Acute ischemic stroke within 45 minutes, large-vessel M1 occlusion, large penumbra, no hemorrhage, patient is candidate for IV thrombolysis and urgent mechanical thrombectomy. The question asks for an additional acute management step consistent with current stroke guidelines.\nChoice C correctly reflects guideline-based care: initiate high-intensity statin early after ischemic stroke and delay antiplatelet therapy for 24 hours post–IV thrombolysis until repeat imaging excludes hemorrhagic transformation. \nOption A (IV heparin before thrombectomy) is contraindicated: routine anticoagulation in acute ischemic stroke, especially around alteplase and thrombectomy, increases hemorrhage risk without outcome benefit. \nOption B describes excessive blood pressure lowering; guidelines permit BP up to 185/110 before tPA and 180/105 after; further lowering may impair perfusion of penumbra. \nOption D (immediate dual antiplatelet therapy after tPA) significantly increases intracranial hemorrhage risk and is avoided. \nOption E (IABP) has no evidence-based role for cerebral perfusion in this setting and carries procedural risk. \nMain medical accuracy issues: none substantive; management logic is guideline-consistent. \nMinimal fix: Clarify in stem that baseline LDL is elevated or that high-intensity statin is indicated per secondary stroke prevention guidelines to reinforce rationale, though not strictly necessary for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-003", "question": "A 34-year-old woman with SLE (malar rash, arthritis, class III lupus nephritis on biopsy) on mycophenolate and low-dose prednisone presents with 3 months of progressive exertional dyspnea and dry cough. She has no smoking history. Vitals: HR 96, BP 112/70, RR 18, SpO2 94% RA. Exam: fine bibasilar crackles, no peripheral edema. Labs: creatinine 1.0 mg/dL, ANA 1:640 homogeneous, anti-dsDNA mildly elevated, complements low, ESR 18 mm/hr, CRP 2 mg/L. PFTs: FVC 65% predicted, FEV1/FVC 0.82, DLCO 40% predicted. HRCT: diffuse ground-glass opacities with scattered areas of consolidation and traction bronchiectasis, predominantly in lower lobes, no honeycombing. BAL: lymphocytic predominance, cultures negative. Echocardiogram: normal LV function, PASP 30 mm Hg. Which of the following is the most appropriate next step in management?", "options": ["Escalate mycophenolate dose and add high-dose oral prednisone without further diagnostics", "Switch mycophenolate to cyclophosphamide and simultaneously list for lung transplantation", "Perform surgical lung biopsy to distinguish organizing pneumonia from NSIP", "Add rituximab while continuing mycophenolate at the same dose", "Initiate nintedanib in addition to current immunosuppression for progressive fibrosing ILD"], "answer": "E", "answer_index": 4, "explanation": "This is SLE-associated progressive fibrosing interstitial lung disease with traction bronchiectasis and physiologic restriction despite immunosuppression; nintedanib has evidence for slowing decline in progressive fibrosing ILDs, including CTD-ILD. Blind escalation of steroids/mycophenolate (A) risks toxicity without clear additional benefit. Routine upfront lung transplant listing (B) is premature. Lung biopsy (C) is high risk and unlikely to alter management given established CTD-ILD pattern. Rituximab (D) can be considered, but antifibrotic therapy specifically targets the progressive fibrosing phenotype and is strongly indicated here.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young woman with established SLE on reasonable baseline immunosuppression (mycophenolate, low-dose prednisone) develops 3 months of progressive exertional dyspnea and dry cough. PFTs show restrictive defect with markedly reduced DLCO. HRCT reveals diffuse ground-glass opacities with areas of consolidation and traction bronchiectasis, basilar predominant, no honeycombing—consistent with connective tissue disease–associated ILD with a progressive fibrosing phenotype. Symptoms and physiology are worsening despite current therapy, renal function is stable, and pulmonary hypertension and infection have been reasonably excluded.\\nOption E (nintedanib) is medically appropriate: antifibrotic therapy has evidence for slowing FVC decline in progressive fibrosing ILDs, including CTD-ILD, when disease progresses on adequate immunosuppression. A is suboptimal blind escalation of immunosuppression; B is premature, as disease is not end-stage; C lung biopsy is unlikely to change management and carries risk; D (rituximab) is a reasonable consideration but less directly supported than antifibrotic therapy for a clearly progressive fibrosing phenotype.\\nMain medical accuracy issues: none substantive; reflects current INBUILD-like data. Minimal fix: Explicitly state serial decline in FVC or worsening HRCT over 6–12 months to more clearly define “progressive” fibrosing ILD.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young woman with established SLE on reasonable baseline immunosuppression (mycophenolate, low-dose prednisone) develops 3 months of progressive exertional dyspnea and dry cough. PFTs show restrictive defect with markedly reduced DLCO. HRCT reveals diffuse ground-glass opacities with areas of consolidation and traction bronchiectasis, basilar predominant, no honeycombing—consistent with connective tissue disease–associated ILD with a progressive fibrosing phenotype. Symptoms and physiology are worsening despite current therapy, renal function is stable, and pulmonary hypertension and infection have been reasonably excluded.\nOption E (nintedanib) is medically appropriate: antifibrotic therapy has evidence for slowing FVC decline in progressive fibrosing ILDs, including CTD-ILD, when disease progresses on adequate immunosuppression. A is suboptimal blind escalation of immunosuppression; B is premature, as disease is not end-stage; C lung biopsy is unlikely to change management and carries risk; D (rituximab) is a reasonable consideration but less directly supported than antifibrotic therapy for a clearly progressive fibrosing phenotype.\nMain medical accuracy issues: none substantive; reflects current INBUILD-like data. Minimal fix: Explicitly state serial decline in FVC or worsening HRCT over 6–12 months to more clearly define “progressive” fibrosing ILD.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-004", "question": "A 51-year-old woman with poorly controlled type 2 diabetes and prior pelvic radiation for cervical cancer presents with 5 days of fever, worsening lower abdominal pain, and foul vaginal discharge. She is hypotensive and tachycardic. Exam: diffuse lower abdominal tenderness with guarding, necrotic friable tissue at the posterior vaginal fornix with gas bubbles and crepitus extending toward the rectovaginal septum. Labs: WBC 19,000/µL, lactate 4.5 mmol/L, creatinine 2.1 mg/dL. CT abdomen/pelvis with contrast: extensive gas in the pelvis tracking along fascial planes into the perineum, no discrete drainable collection, suspected uterine and vaginal wall necrosis. Blood cultures are drawn, and broad-spectrum IV antibiotics and aggressive fluids are started. Which is the most appropriate next step?", "options": ["Urgent total abdominal hysterectomy with wide radical debridement of necrotic pelvic and perineal tissue", "Percutaneous CT-guided drainage of gas-containing pelvic spaces plus continued maximal antibiotics", "Hyperbaric oxygen therapy as a temporizing measure before any surgical intervention", "Emergent exploratory laparotomy limited to diagnostic assessment and peritoneal lavage", "Conservative management with antibiotics and close ICU monitoring to avoid worsening radiation injury"], "answer": "A", "answer_index": 0, "explanation": "The clinical picture is necrotizing pelvic soft tissue infection (type I Fournier-like process) involving uterus and vagina in a radiated field, requiring immediate radical surgical debridement including hysterectomy. Percutaneous drainage (B) is inadequate for necrotizing fasciitis. Hyperbaric oxygen (C) may be adjunctive but never replaces urgent debridement. Exploratory laparotomy without aggressive debridement (D) fails to control source. Conservative management (E) carries an almost universally fatal risk in necrotizing infections.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\n\\nKey stem clues: poorly controlled diabetes, prior pelvic radiation, 5 days of fever and worsening lower abdominal pain, foul vaginal discharge, hypotension, tachycardia, guarding, necrotic friable vaginal tissue with gas bubbles and crepitus tracking toward rectovaginal septum, leukocytosis, elevated lactate, CT showing extensive gas along fascial planes without discrete collection and suspected uterine/vaginal wall necrosis. This constellation indicates a necrotizing pelvic soft-tissue infection (Fournier-like) with septic shock, requiring immediate radical surgical source control.\\n\\nChoice A (urgent total abdominal hysterectomy with wide radical debridement) is consistent with standard management of necrotizing fasciitis in a radiated pelvic field with uterine/vaginal wall necrosis.\\n\\nB (percutaneous drainage) is inappropriate because necrotizing fasciitis requires wide debridement, not drainage alone.\\n\\nC (hyperbaric oxygen) is only adjunctive and never replaces emergent surgery.\\n\\nD (diagnostic-only laparotomy and lavage) fails to provide definitive source control.\\n\\nE (conservative management) is contraindicated and nearly always fatal in necrotizing infections.\\n\\nMain medical accuracy issues: None significant; teaching point is correct and contemporary.\\n\\nMinimal fix: Explicitly add the word “necrotizing fasciitis” or “necrotizing soft tissue infection” in the CT impression to further anchor the intended diagnosis, though current wording is already adequate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\n\nKey stem clues: poorly controlled diabetes, prior pelvic radiation, 5 days of fever and worsening lower abdominal pain, foul vaginal discharge, hypotension, tachycardia, guarding, necrotic friable vaginal tissue with gas bubbles and crepitus tracking toward rectovaginal septum, leukocytosis, elevated lactate, CT showing extensive gas along fascial planes without discrete collection and suspected uterine/vaginal wall necrosis. This constellation indicates a necrotizing pelvic soft-tissue infection (Fournier-like) with septic shock, requiring immediate radical surgical source control.\n\nChoice A (urgent total abdominal hysterectomy with wide radical debridement) is consistent with standard management of necrotizing fasciitis in a radiated pelvic field with uterine/vaginal wall necrosis.\n\nB (percutaneous drainage) is inappropriate because necrotizing fasciitis requires wide debridement, not drainage alone.\n\nC (hyperbaric oxygen) is only adjunctive and never replaces emergent surgery.\n\nD (diagnostic-only laparotomy and lavage) fails to provide definitive source control.\n\nE (conservative management) is contraindicated and nearly always fatal in necrotizing infections.\n\nMain medical accuracy issues: None significant; teaching point is correct and contemporary.\n\nMinimal fix: Explicitly add the word “necrotizing fasciitis” or “necrotizing soft tissue infection” in the CT impression to further anchor the intended diagnosis, though current wording is already adequate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-005", "question": "A 76-year-old man with permanent atrial fibrillation on apixaban, CKD stage 3b, and prior TIA undergoes TAVR for symptomatic severe aortic stenosis. Preprocedure echo: EF 55%, no intracardiac thrombus, moderate MAC, mild-moderate MR. Postprocedure, he develops acute severe dyspnea and hypotension 2 hours later. Echo: hyperdynamic LV with near-complete mid-cavity obliteration in systole, peak LVOT gradient 80 mm Hg, systolic anterior motion (SAM) of the mitral valve, severe MR, intact TAVR function. Which of the following is the most appropriate immediate management?", "options": ["Start high-dose IV furosemide and nitroprusside to rapidly reduce preload and afterload", "Administer aggressive IV crystalloids and start a phenylephrine infusion while reducing inotropes", "Urgently return to the cath lab for balloon post-dilatation of the TAVR prosthesis", "Begin IV milrinone infusion to augment contractility and improve forward flow", "Perform emergent surgical myectomy with mitral valve repair"], "answer": "B", "answer_index": 1, "explanation": "This is dynamic LVOT obstruction with SAM and severe MR precipitated by TAVR and low preload; management mirrors hypertrophic obstructive physiology-volume expansion and pure alpha-agonist (phenylephrine) to increase afterload while avoiding inotropes. Diuresis and vasodilators (A) and inotropes (D) worsen obstruction. Post-dilatation of the valve (C) is not indicated as prosthetic function is normal. Emergent surgery (E) is reserved for refractory cases after optimal medical hemodynamic management has failed.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Post-TAVR patient with acute hypotension and severe dyspnea; echo shows hyperdynamic LV, near-complete mid-cavity obliteration, systolic anterior motion (SAM) of the mitral valve, high LVOT gradient (80 mm Hg), severe MR, and intact TAVR function. These findings are classic for dynamic LVOT obstruction with SAM in a low-preload, high-contractility state. Immediate management parallels hypertrophic obstructive cardiomyopathy physiology: increase preload and afterload, avoid inotropes/vasodilators/diuresis.\\nOption B (aggressive IV crystalloid plus phenylephrine while reducing inotropes) directly addresses this: volume expansion, pure alpha-agonist to raise afterload, and removal of inotropic drive. A (diuresis + nitroprusside) would decrease preload/afterload and worsen obstruction; D (milrinone) increases inotropy and vasodilation, also worsening obstruction. C is inappropriate because the valve is functioning normally. E (emergent surgery) is not first-line and is reserved for refractory cases.\\nMain medical accuracy issue(s): None; pathophysiology and management are consistent with current understanding.\\nMinimal fix: Add an explicit note that vasopressors/inotropes had been started post-procedure (or that he is on inotropes) to justify “reducing inotropes” in choice B, though this is minor and implied by context.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Post-TAVR patient with acute hypotension and severe dyspnea; echo shows hyperdynamic LV, near-complete mid-cavity obliteration, systolic anterior motion (SAM) of the mitral valve, high LVOT gradient (80 mm Hg), severe MR, and intact TAVR function. These findings are classic for dynamic LVOT obstruction with SAM in a low-preload, high-contractility state. Immediate management parallels hypertrophic obstructive cardiomyopathy physiology: increase preload and afterload, avoid inotropes/vasodilators/diuresis.\nOption B (aggressive IV crystalloid plus phenylephrine while reducing inotropes) directly addresses this: volume expansion, pure alpha-agonist to raise afterload, and removal of inotropic drive. A (diuresis + nitroprusside) would decrease preload/afterload and worsen obstruction; D (milrinone) increases inotropy and vasodilation, also worsening obstruction. C is inappropriate because the valve is functioning normally. E (emergent surgery) is not first-line and is reserved for refractory cases.\nMain medical accuracy issue(s): None; pathophysiology and management are consistent with current understanding.\nMinimal fix: Add an explicit note that vasopressors/inotropes had been started post-procedure (or that he is on inotropes) to justify “reducing inotropes” in choice B, though this is minor and implied by context.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-006", "question": "A 42-year-old man who injects drugs presents with 10 days of fever, severe back pain, and new right leg weakness. Vitals: T 38.8°C, HR 108, BP 122/74. Exam: midline lumbar tenderness, right leg 3/5 strength with hyperreflexia, left leg 5/5, intact sensation, no bowel/bladder symptoms. Labs: WBC 15,000/µL, ESR 96 mm/hr, CRP 120 mg/L. Blood cultures: MRSA in 2/2 sets. MRI lumbar spine with contrast: dorsal epidural collection L2-L4 with significant canal compromise and enhancement consistent with epidural abscess, plus adjacent vertebral osteomyelitis; no discrete psoas abscess. He is started on IV vancomycin. Neurosurgery feels surgery is high risk due to severe cardiomyopathy (EF 20%) and active drug use, recommending medical therapy unless deterioration. What is the most appropriate next step?", "options": ["Continue IV vancomycin alone with close neurologic monitoring for at least 6 weeks", "Add rifampin to vancomycin to enhance penetration into epidural space and bone", "Perform urgent surgical decompression and drainage despite high perioperative risk", "Switch to daptomycin plus ceftaroline to provide broader MRSA coverage", "Place percutaneous CT-guided drain into the epidural collection to avoid open surgery"], "answer": "C", "answer_index": 2, "explanation": "He has spinal epidural abscess with evolving motor deficit and significant canal compromise; urgent surgical decompression and drainage is indicated despite elevated operative risk, as delay risks permanent paralysis. Medical therapy alone (A, B, D) is inadequate once neurologic deficits are present. Percutaneous drainage (E) is not appropriate for epidural abscess causing cord compression, as it rarely achieves effective decompression or safe access to the epidural space.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 10 days of fever and severe back pain; IVDU; MRSA bacteremia; MRI showing dorsal lumbar epidural abscess with significant canal compromise plus vertebral osteomyelitis; new unilateral leg weakness (3/5) with hyperreflexia indicating spinal cord/nerve root compression; neurosurgery recommending conservative care due to high operative risk. These findings meet classic indications for urgent surgical decompression and drainage of a spinal epidural abscess despite comorbidities, to prevent irreversible neurologic injury.\\nOption C correctly prioritizes decompression over medical risk concerns. A, B, and D are medical-therapy-only approaches that are inappropriate once a neurologic deficit and canal compromise are present. E (percutaneous drain) is generally not feasible or sufficient for epidural abscess causing compression, and is properly rejected in the explanation.\\nNo major medical inaccuracies: this aligns with standard spinal epidural abscess management. The ethical/clinical teaching point (operative indication despite high risk) is clear and board-consistent.\\nMinimal fix: Explicitly state “progressive” or “new neurologic deficit over 10 days” in the stem, or add a line that neurosurgery is consulted specifically for decompression, to more clearly link findings to surgical indication and avoid any perceived ambiguity about stability of deficit.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 10 days of fever and severe back pain; IVDU; MRSA bacteremia; MRI showing dorsal lumbar epidural abscess with significant canal compromise plus vertebral osteomyelitis; new unilateral leg weakness (3/5) with hyperreflexia indicating spinal cord/nerve root compression; neurosurgery recommending conservative care due to high operative risk. These findings meet classic indications for urgent surgical decompression and drainage of a spinal epidural abscess despite comorbidities, to prevent irreversible neurologic injury.\nOption C correctly prioritizes decompression over medical risk concerns. A, B, and D are medical-therapy-only approaches that are inappropriate once a neurologic deficit and canal compromise are present. E (percutaneous drain) is generally not feasible or sufficient for epidural abscess causing compression, and is properly rejected in the explanation.\nNo major medical inaccuracies: this aligns with standard spinal epidural abscess management. The ethical/clinical teaching point (operative indication despite high risk) is clear and board-consistent.\nMinimal fix: Explicitly state “progressive” or “new neurologic deficit over 10 days” in the stem, or add a line that neurosurgery is consulted specifically for decompression, to more clearly link findings to surgical indication and avoid any perceived ambiguity about stability of deficit.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-007", "question": "A 31-year-old woman presents with severe headaches, transient visual obscurations, and pulsatile tinnitus 6 months postpartum. She has gained 20 kg during and after pregnancy. BMI is 38 kg/m². Exam: bilateral papilledema, full strength, no focal deficits. MRI brain with and without contrast is normal. MRV shows smooth tapering and non-visualization of the terminal right transverse sinus with small caliber sigmoid sinus and jugular bulb; the left transverse sinus is dominant and widely patent. Lumbar puncture: opening pressure 34 cm H₂O, normal CSF studies. She is started on acetazolamide and advised weight loss but continues to have progressive visual field loss on serial perimetry over 8 weeks. What is the most appropriate next step in management?", "options": ["Place a ventriculoperitoneal shunt to lower intracranial pressure", "Perform right transverse sinus stenting across the narrowed segment", "Initiate high-dose oral topiramate instead of acetazolamide", "Perform optic nerve sheath fenestration to protect vision", "Start therapeutic anticoagulation for presumed chronic venous sinus thrombosis"], "answer": "D", "answer_index": 3, "explanation": "The patient has idiopathic intracranial hypertension with rapidly progressive visual loss despite maximal medical therapy; optic nerve sheath fenestration is the preferred intervention to promptly protect vision. VP shunting (A) is an option but has higher long-term failure and complication rates and is usually considered after or when ONSF is not feasible. Transverse sinus stenting (B) is usually reserved for documented significant pressure gradients and bilateral or dominant-sided stenosis; here the right sinus is small and nondominant. Topiramate (C) is an adjunct but insufficient alone given progressive visual decline. Anticoagulation (E) is not indicated without imaging evidence of thrombosis.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Young obese woman, postpartum, with headache, papilledema, normal MRI, MRV with small/nondominant right transverse sinus but patent dominant left sinus, elevated LP opening pressure (34 cm H₂O), consistent with idiopathic intracranial hypertension. Despite acetazolamide and weight loss, she has progressive visual field loss over 8 weeks, making this a vision-threatening, medically refractory case. The primary urgent goal is protection of vision.\\nOption D (optic nerve sheath fenestration) directly addresses papilledema and is standard next step to rapidly protect vision in IIH with progressive visual loss despite maximal medical therapy. A (VP shunt) lowers ICP but is generally chosen when broader ICP symptoms predominate or ONSF is not feasible; also has higher failure/complication rates. B (stenting) is not indicated without demonstrable pressure gradient or dominant/bilateral stenosis. C (topiramate) is adjunctive and inadequate for rapidly progressive loss. E (anticoagulation) is inappropriate given no evidence of thrombosis on MRV.\\nMain medical accuracy issues: None significant; rationale reflects current practice. Minimal fix: Explicitly state that acetazolamide is at maximal tolerated dose to reinforce “failed maximal medical therapy.”\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Young obese woman, postpartum, with headache, papilledema, normal MRI, MRV with small/nondominant right transverse sinus but patent dominant left sinus, elevated LP opening pressure (34 cm H₂O), consistent with idiopathic intracranial hypertension. Despite acetazolamide and weight loss, she has progressive visual field loss over 8 weeks, making this a vision-threatening, medically refractory case. The primary urgent goal is protection of vision.\nOption D (optic nerve sheath fenestration) directly addresses papilledema and is standard next step to rapidly protect vision in IIH with progressive visual loss despite maximal medical therapy. A (VP shunt) lowers ICP but is generally chosen when broader ICP symptoms predominate or ONSF is not feasible; also has higher failure/complication rates. B (stenting) is not indicated without demonstrable pressure gradient or dominant/bilateral stenosis. C (topiramate) is adjunctive and inadequate for rapidly progressive loss. E (anticoagulation) is inappropriate given no evidence of thrombosis on MRV.\nMain medical accuracy issues: None significant; rationale reflects current practice. Minimal fix: Explicitly state that acetazolamide is at maximal tolerated dose to reinforce “failed maximal medical therapy.”", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-008", "question": "A 29-year-old woman with a history of two early first-trimester miscarriages and one unexplained fetal demise at 28 weeks presents for preconception counseling. She has livedo reticularis and episodes of digital ischemia in cold weather. Labs: platelets 110,000/µL, hemoglobin 11.5 g/dL, creatinine 0.9 mg/dL. Coagulation profile is normal. aPTT is mildly prolonged. Lupus anticoagulant is repeatedly positive; anticardiolipin IgG and anti-β2-glycoprotein I IgG are high-titer on two occasions 12 weeks apart. She has no personal history of venous or arterial thrombosis. Which of the following is the most appropriate pregnancy management plan?", "options": ["Low-dose aspirin alone starting preconception, escalate to prophylactic LMWH only if thrombosis occurs", "Therapeutic-dose LMWH plus low-dose aspirin starting at positive pregnancy test and continuing 6 weeks postpartum", "Prophylactic-dose LMWH plus low-dose aspirin starting at conception and stopping at delivery", "Low-dose aspirin only during pregnancy, with postpartum prophylactic LMWH for 6 weeks", "No anticoagulation unless she develops hypertensive disorders of pregnancy"], "answer": "B", "answer_index": 1, "explanation": "She meets criteria for high-risk obstetric antiphospholipid syndrome with recurrent pregnancy loss and triple-positive aPL; therapeutic-dose LMWH plus low-dose aspirin throughout pregnancy and 6 weeks postpartum provides optimal maternal and fetal protection. Aspirin alone (A, D, E) is inadequate in high-risk APS. Prophylactic-dose LMWH (C) may be used in lower-risk obstetric APS but is insufficient here given triple positivity and prior late fetal loss and thrombocytopenia suggestive of high thrombotic risk.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: M (multiple answers defensible; also partially misinterprets guidelines)\\nVerdict on keyed answer: Not uniquely determinable\\nKey stem clues: Recurrent early miscarriages plus unexplained fetal demise at 28 weeks; triple-positive antiphospholipid antibodies documented twice; mild thrombocytopenia; livedo and digital ischemia but no *documented* venous/arterial thrombosis; question asks about pregnancy management. These findings satisfy criteria for obstetric antiphospholipid syndrome without prior thrombosis.\\nMain logical issue(s): For isolated obstetric APS (no prior thrombosis), major guidelines (ACR/ACOG/ESHRE/ASRM) generally recommend low‑dose aspirin plus **prophylactic‑dose** LMWH during pregnancy and postpartum. Use of full **therapeutic‑dose** LMWH is usually reserved for patients with prior thrombosis or other clear indications, which the stem explicitly denies. Thus option C is strongly guideline‑concordant, while B over-treats relative to standard recommendations. The explanation’s justification that “triple positivity and thrombocytopenia” alone mandate therapeutic dosing is not clearly evidence-based, making C at least as defensible as B.\\nMain medical accuracy issue(s): Overstatement that therapeutic LMWH is “optimal” and that prophylactic dosing is “insufficient” in this scenario.\\nMinimal fix: Change option C to “therapeutic-dose LMWH” and/or add a prior thrombosis history to the stem to clearly justify B as best.\\n\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (multiple answers defensible; also partially misinterprets guidelines)\nVerdict on keyed answer: Not uniquely determinable\nKey stem clues: Recurrent early miscarriages plus unexplained fetal demise at 28 weeks; triple-positive antiphospholipid antibodies documented twice; mild thrombocytopenia; livedo and digital ischemia but no *documented* venous/arterial thrombosis; question asks about pregnancy management. These findings satisfy criteria for obstetric antiphospholipid syndrome without prior thrombosis.\nMain logical issue(s): For isolated obstetric APS (no prior thrombosis), major guidelines (ACR/ACOG/ESHRE/ASRM) generally recommend low‑dose aspirin plus **prophylactic‑dose** LMWH during pregnancy and postpartum. Use of full **therapeutic‑dose** LMWH is usually reserved for patients with prior thrombosis or other clear indications, which the stem explicitly denies. Thus option C is strongly guideline‑concordant, while B over-treats relative to standard recommendations. The explanation’s justification that “triple positivity and thrombocytopenia” alone mandate therapeutic dosing is not clearly evidence-based, making C at least as defensible as B.\nMain medical accuracy issue(s): Overstatement that therapeutic LMWH is “optimal” and that prophylactic dosing is “insufficient” in this scenario.\nMinimal fix: Change option C to “therapeutic-dose LMWH” and/or add a prior thrombosis history to the stem to clearly justify B as best.\n", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-009", "question": "A 55-year-old man from a region endemic for Lyme disease presents with 1 week of rapidly progressive bilateral leg weakness and numbness ascending from the feet, severe radicular pain, and new urinary retention. He was treated with oral doxycycline 3 weeks ago for erythema migrans following a hiking trip. Exam: symmetric lower extremity weakness 3/5 proximally and distally, hyperreflexia with bilateral Babinski signs, decreased pinprick below T10, preserved vibration sense in toes, and saddle hypesthesia. Cranial nerves are normal. MRI spine with contrast: multifocal enhancing lesions in the thoracic cord with associated leptomeningeal enhancement; no compressive lesion. CSF: WBC 220/µL (80% lymphocytes), protein 120 mg/dL, glucose 45 mg/dL (serum 90), oligoclonal bands present; CSF Lyme antibody index is elevated. HIV, syphilis, and TB tests are negative. What is the most appropriate treatment?", "options": ["High-dose IV methylprednisolone alone for presumed idiopathic transverse myelitis", "IV ceftriaxone 2 g daily for 4 weeks without steroids", "IV ceftriaxone 2 g daily plus high-dose IV methylprednisolone", "Oral doxycycline 100 mg BID for 28 days plus high-dose oral prednisone taper", "Plasma exchange for 5-7 sessions followed by IV ceftriaxone"], "answer": "B", "answer_index": 1, "explanation": "This is Lyme neuroborreliosis with meningomyelitis confirmed by elevated CSF Lyme antibody index and appropriate clinical picture; standard treatment is prolonged IV ceftriaxone without routine adjunctive steroids. Steroids alone (A) are inappropriate and may worsen infection. Adding high-dose steroids to antibiotics (C) has no proven benefit and may be harmful. Oral doxycycline (D) is inadequate for CNS parenchymal involvement. Plasma exchange (E) is used in severe autoimmune demyelination (e.g., NMO, ADEM) and is not indicated here once Lyme is confirmed.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: subacute (1 week) ascending leg weakness with upper motor neuron signs (hyperreflexia, Babinski), sensory level at T10, saddle hypesthesia, urinary retention, MRI showing enhancing thoracic cord and leptomeningeal enhancement, CSF lymphocytic pleocytosis with elevated protein, low CSF:serum glucose, oligoclonal bands, and elevated CSF Lyme antibody index in a man recently treated for erythema migrans in an endemic area. These firmly establish Lyme meningomyelitis/neuroborreliosis with CNS parenchymal involvement.\\nTreatment standard for CNS Lyme with meningitis/myelitis is IV ceftriaxone for 2–4 weeks; options with steroids alone (A), combined high-dose steroids (C), oral doxycycline (D), or plasma exchange (E) are not recommended first-line and may be harmful or unnecessary. Current evidence does not support routine adjunctive corticosteroids in Lyme neuroborreliosis, especially when diagnosis is established.\\nMain logical issues: None—stem is rich, internally consistent, and strongly points to a unique best answer (B).\\nMain medical accuracy issues: Minor—duration phrased as 4 weeks is acceptable within guideline ranges.\\nMinimal fix: Specify guideline-based duration range in the stem or explanation (e.g., “2–4 weeks”) to reflect typical practice, but this is not required for item validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: subacute (1 week) ascending leg weakness with upper motor neuron signs (hyperreflexia, Babinski), sensory level at T10, saddle hypesthesia, urinary retention, MRI showing enhancing thoracic cord and leptomeningeal enhancement, CSF lymphocytic pleocytosis with elevated protein, low CSF:serum glucose, oligoclonal bands, and elevated CSF Lyme antibody index in a man recently treated for erythema migrans in an endemic area. These firmly establish Lyme meningomyelitis/neuroborreliosis with CNS parenchymal involvement.\nTreatment standard for CNS Lyme with meningitis/myelitis is IV ceftriaxone for 2–4 weeks; options with steroids alone (A), combined high-dose steroids (C), oral doxycycline (D), or plasma exchange (E) are not recommended first-line and may be harmful or unnecessary. Current evidence does not support routine adjunctive corticosteroids in Lyme neuroborreliosis, especially when diagnosis is established.\nMain logical issues: None—stem is rich, internally consistent, and strongly points to a unique best answer (B).\nMain medical accuracy issues: Minor—duration phrased as 4 weeks is acceptable within guideline ranges.\nMinimal fix: Specify guideline-based duration range in the stem or explanation (e.g., “2–4 weeks”) to reflect typical practice, but this is not required for item validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124", "question_id": "20251129T045001943Z_gpt-5.1-2025-11-13_seed124-010", "question": "A 48-year-old woman with seropositive rheumatoid arthritis (RF and anti-CCP positive) on methotrexate and adalimumab presents with subacute dyspnea and nonproductive cough. She has never smoked. Vitals: HR 104, BP 118/70, RR 22, SpO2 91% RA. Exam: fine bibasilar crackles, no wheezing, active small-joint synovitis. PFTs: FVC 58% predicted, FEV1/FVC 0.86, DLCO 35% predicted. HRCT: basilar-predominant reticulation, traction bronchiectasis, and patchy subpleural honeycombing consistent with usual interstitial pneumonia (UIP); no nodules or pleural effusions. Which of the following is the most appropriate disease-modifying management change?", "options": ["Continue methotrexate and adalimumab and add low-dose prednisone", "Discontinue methotrexate and switch adalimumab to rituximab", "Stop adalimumab and start tocilizumab while continuing methotrexate", "Continue current RA regimen and initiate mycophenolate mofetil for lung disease", "Add nintedanib while continuing methotrexate and adalimumab unchanged"], "answer": "B", "answer_index": 1, "explanation": "She has RA-associated ILD with a UIP pattern, in which methotrexate and TNF inhibitors are relatively contraindicated due to concerns for ILD progression; rituximab is preferred as an RA biologic in ILD. Continuing MTX/TNF with steroids (A) risks worsening lung fibrosis. Tocilizumab (C) has less data and does not address TNF-risk concerns. Adding mycophenolate (D) without removing potential pulmonary offenders is suboptimal. Nintedanib (E) may be beneficial in progressive fibrosing RA-ILD, but first-line is to remove MTX/TNF and choose an ILD-favorable biologic such as rituximab.", "generator_model": "gpt-5.1-2025-11-13", "seed": 124, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Middle-aged woman with long-standing seropositive RA on methotrexate and a TNF inhibitor (adalimumab), now with subacute dyspnea, restrictive PFTs and severely reduced DLCO, and HRCT showing basilar-predominant reticulation, traction bronchiectasis, and subpleural honeycombing consistent with RA-associated ILD with a UIP pattern. Question asks for the most appropriate disease-modifying management change.\\nMethotrexate and TNF inhibitors are generally avoided or discontinued in clinically significant RA-ILD due to concern for progression; rituximab is the biologic with the strongest supportive data and guideline preference in RA-ILD. Thus, discontinuing methotrexate and switching adalimumab to rituximab (B) is the best single choice.\\nOther options: (A) continues both potential offenders, only adds steroids; (C) keeps methotrexate and does not address TNF-risk concerns; (D) adds mycophenolate but leaves suspected offending agents in place; (E) adds an antifibrotic without adjusting RA regimen, which is nonstandard as first disease-modifying step.\\nMain medical accuracy: Reasoning is consistent with current rheumatology/ILD guidance; minor ongoing debate about methotrexate lung risk, but in this context discontinuation is defensible. Minimal fix: Clarify that her ILD is new/progressing despite current RA regimen to further justify changing DMARDs.\\n\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Middle-aged woman with long-standing seropositive RA on methotrexate and a TNF inhibitor (adalimumab), now with subacute dyspnea, restrictive PFTs and severely reduced DLCO, and HRCT showing basilar-predominant reticulation, traction bronchiectasis, and subpleural honeycombing consistent with RA-associated ILD with a UIP pattern. Question asks for the most appropriate disease-modifying management change.\nMethotrexate and TNF inhibitors are generally avoided or discontinued in clinically significant RA-ILD due to concern for progression; rituximab is the biologic with the strongest supportive data and guideline preference in RA-ILD. Thus, discontinuing methotrexate and switching adalimumab to rituximab (B) is the best single choice.\nOther options: (A) continues both potential offenders, only adds steroids; (C) keeps methotrexate and does not address TNF-risk concerns; (D) adds mycophenolate but leaves suspected offending agents in place; (E) adds an antifibrotic without adjusting RA regimen, which is nonstandard as first disease-modifying step.\nMain medical accuracy: Reasoning is consistent with current rheumatology/ILD guidance; minor ongoing debate about methotrexate lung risk, but in this context discontinuation is defensible. Minimal fix: Clarify that her ILD is new/progressing despite current RA regimen to further justify changing DMARDs.\n", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}]